Monte Rosa Therapeutics Long Term Debt

Monte Rosa Therapeutics (GLUE) currently reports a long-term debt of $33M as of June 2026. That compares with $74M in the prior-year period — down 55.0% year over year. Use the charts on this page to explore Monte Rosa Therapeutics's long-term debt history and peer comparisons.

Monte Rosa Therapeutics's long-term debt decreased from $74M to $33M — a 55.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics reported $33M in long-term debt as of June 2026. That compares with $74M in the prior-year period — down 55.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.

Monte Rosa Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $33M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLUE with unrelated industries.